TIGIT is upregulated on T cells, Tregs and NK cells in the tumor microenvironment (TME) of some tumor types. It inhibits their activity and prohibits CD226-mediated immune activation. TIGIT expression is a marker of exhausted T cells and immunosuppressive Tregs in the TME.1-9
M6223 is an investigational fully human IgG1 anti-TIGIT antibody with Fc effector function. By blocking the interaction between TIGIT and its ligand, CD155, M6223 is thought to reduce TIGIT-mediated T cell immunosuppression.10,11
M6223 is thought to restore T cell and NK cell activity, enable CD226-mediated immune activation, and is designed to deplete exhausted T cells and suppressive Tregs in the TME via the Fc-mediated effector function.5-9,11,12
M6223 is being investigated in a first-in-human, Phase I, open-label, dose-escalation study as a monotherapy and in combination with bintrafusp alfa, in patients with metastatic or locally advanced solid unresectable tumors.LEARN ABOUT COMPANY SPONSORED CLINICAL TRIALS LEARN ABOUT ALL CLINICAL TRIALS
Fc, fragment crystallizable; IgG1, immunoglobulin G1; mAb, monoclonal antibody; NK, natural killer; PD-L1, programmed death-ligand 1; TGF-β, transforming growth factor-β; TIGIT, T-cell immunoglobulin and ITIM domain; Treg, regulatory T cell.